Karyopharm Therapeutics | KPTI - Interest Expense On Debt


Karyopharm Therapeutics reported $12.55M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Abbott USD 299M 231M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
AstraZeneca USD 340M 144M Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
GlaxoSmithKline GBP 121M 46M Jun/2026
Incyte USD 582K 13K Jun/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
MacroGenics USD 4.89M 1.55M Mar/2026
Merck USD 525M 46M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Novartis USD 462M 119M Jun/2026
Novartis USD 281M 8M Sep/2025
Pfizer USD 667M 4M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Takeda JPY 63.85B 20.2B Jun/2026
Tectonic Therapeutic USD 246.58M 246.56M Mar/2026
TG Therapeutics USD 16.57M 8.91M Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Xencor USD 7.35M 2.65M Jun/2026